Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy?

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 5663-5679

  Barresi, Valeria ^a   Branca, Giovann ^a   Caffo, Maria ^a   Caltabiano, Rosario ^b   Ieni, Antonio ^a   Vitarelli, Enrica ^a   Lanzafame, Salvatore ^b   Tuccari, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Angiogenesis; Brain metastasis; Endoglin; MVD; Pericytes

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOGLIN; SMOOTH MUSCLE ACTIN; ACTA2 PROTEIN, HUMAN; ACTIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN BLOOD VESSEL; BRAIN METASTASIS; BRAIN PERICYTE; CANCER TISSUE; CAPILLARY DENSITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN; BRAIN NEOPLASMS; NEOPLASM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS; SECONDARY; VASCULARIZATION;

ACTINS; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; BRAIN; BRAIN NEOPLASMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898755443     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15045663     Document Type: Article

References (53)

1. Liu, Y.; Carson-Walter, E. B.; Cooper, A.; Winans, B. N.; Johnson, M. D.; Walter, K. A. Vascular gene expression patterns are conserved in primitive and metastatic brain tumors. J. Neurooncol. 2010, 99, 13-24.
2. Hall, W. A.; Djalilian, H. R.; Nussbaum, E. S.; Cho, K. H. Longterm survival with metastatic cancer to the brain. Med. Oncol. 2000, 7, 279-286.
3. Kolomainen, D. F.; Larkin, J. M.; Badran, M.; A'Hern, R. P.; King, D. M.; Fisher, C.; Bridges, J. E.; Blake, P. R.; Barton, D. P.; Shepherd, J. H.; et al. Epithelial ovarian cancer metastasizing to the brain: A late manifestation of the disease with an increasing incidence. J. Clin. Oncol. 2002, 20, 982-986.
4. Kyritsis, A. P.; Markoula, S.; Levin, V. A. A systematic approach to the management of patients with brain metastases of known or unknown primitive site. Cancer Chemother. Pharmacol. 2012, 69, 1-13.
5. Fidler, I. J. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 2011, 21, 107-112.
6. Jahroudi, N.; Greenberger, J. S. The role of endothelial cells in tumor invasion and metastasis. J. Neurooncol. 1995, 23, 99-108.
7. Nicolson, G. L.; Menter, D. G.; Herrmann, J. L.; Yun, Z.; Cavanaugh, P.; Marchetti, D. Brain metastasis: Role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the central nervous system. Curr. Top. Microbiol. Immunol. 1996, 213, 89-115.
8. Yano, S.; Shinohara, H.; Herbst, R. S.; Kuniyasu, H.; Bucana, C. D.; Ellis, L.; Davis, D. W.; McConkey, D. J.; Fidler, I. J. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000, 60, 4959-4967.
9. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
10. Kim, L. S.; Huang, S.; Lu, W.; Lev, D. C.; Price, J. E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 2004, 21, 107-118.
11. Carmeliet, P.; Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298-307.
12. Labidi, S. I.; Bachelot, T.; Ray-Coquard, I.; Mosbah, K.; Mosbah, K.; Treilleux, I.; Fayette, J.; Favier, B.; Galy, G.; Blay, J. Y.; et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: A case series. Clin. Breast Cancer 2009, 9, 118-121.
13. De Braganca, K. C.; Janjigian, Y. Y.; Azzoli, G. C.; Kris, M. G.; Pietanza, M. C.; Nolan, C. P.; Omuro, A. M.; Holodny, A. I.; Lassman, A. B. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol. 2010, 100, 443-447.
14. Besse, B.; Lasserre, S. F.; Compton, P.; Huang, J.; Augustus, S.; Rohr, U. P. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 2010, 16, 69-78.
15. Danciu, O. C.; Rayani, S.; Michals, E. A.; Villano, J. L. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med. Oncol. 2012, 29, 2619-2622.
16. Yamamoto, D.; Iwase, S.; Tsubota, Y.; Sueoka, N.; Yamamoto, C.; Kitamura, K.; Odagiri, H.; Nagumo, Y. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther. 2012, 5, 185-189.
17. Cook, K. M.; Figg, W. D. Angiogenesis inhibitors, current strategies and future prospects. CA Cancer J. Clin. 2010, 60, 222-243.
18. Choueiri, T. K.; Duh, M. S.; Clement, J.; Brick, A. J.; Rogers, M. J.; Kwabi, C.; Shah, K.; Percy, A. G.; Antràs, L.; Jayawant, S. S.; et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma, effectiveness; safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010, 105, 1247-1254.
19. Donnem, T.; Hu, J.; Ferguson, M.; Adighibe, O.; Snell, C.; Harris, A. L.; Gatter, K. C.; Pezzella, F. Vessel co-option in primary human tumors and metastases: An obstacle to effective anti-angiogenic treatment? Cancer Med. 2013, 2, 427-436.
20. Alon, T.; Hemo, I.; Itin, A.; Pe'er, J.; Stone, J.; Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995, 1, 1024-1028.
21. Benjamin, L. E.; Hemo, I.; Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125, 1591-1598.
22. Helfrich, I.; Scheffrahn, I.; Bartling, S.; Weis, J.; von Felbert, V.; Middleton, M.; Kato, M.; Ergün, S.; Augustin, H. G.; Schadendorf, D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 2010, 207, 491-503.
23. Barresi, V.; Cerasoli, S.; Vitarelli, E.; Tuccari, G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol. 2007, 114, 147-156.
24. Cheifetz, S.; Bellón, T.; Calés, C.; Vera, S.; Bernabeu, C.; Massagué, J.; Letarte, M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 1992, 267, 19027-19030.
25. Folkman, J. Tumor angiogenesis, therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
26. Madhusudan, S.; Harris, A. L. Drug inhibition of angiogenesis. Curr. Opin. Pharmacol. 2002, 2, 403-414.
27. El-Kenawi, A. E.; El-Remessy, A. B. Angiogenesis inhibitors in cancer therapy, mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol. 2013, 170, 712-729.
28. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; et al. AVOREN Trial investigators Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma, a randomised; double-blind phase III trial. Lancet 2007, 370, 2103-2111.
29. Ince, W. L.; Jubb, A. M.; Holden, S. N.; Holmgren, E. B.; Tobin, P.; Sridhar, M.; Hurwitz, H. I.; Kabbinavar, F.; Novotny, W. F.; Hillan, K. J.; et al. Association of k-ras; b-raf; and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst. 2005, 97, 981-989.
30. Jubb, A. M.; Hurwitz, H. I.; Bai, W.; Holmgren, E. B.; Tobin, P.; Guerrero, A. S.; Kabbinavar, F.; Holden, S. N.; Novotny, W. F.; Frantz, G. D.; et al. Impact of vascular endothelial growth factor-A expression; thrombospondin-2 expression; and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006, 24, 217-227.
31. Jubb, A. M.; Cesario, A.; Ferguson, M.; Congedo, M. T.; Gatter, K. C.; Lococo, F.; Mulè, A.; Pezzella, F. Vascular phenotypes in primitive non-small cell lung carcinomas and matched brain metastases. Br. J. Cancer 2011, 104, 1877-1881.
32. Salgado, K. B.; Toscani, N. V.; Silva, L. L.; Hilbig, A.; Barbosa-Coutinho, L. M. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma, evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 2007, 24, 403-410.
33. Burrows, F. J.; Derbyshire, E. J.; Tazzari, P. L.; Amlot, P.; Gazdar, A. F.; King, S. W.; Letarte, M.; Vitetta, E. S.; Thorpe, P. E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors, implications for diagnosis and therapy. Clin. Cancer Res. 1995, 1, 1623-1634.
34. Auguste, P.; Lemiere, S.; Larrieu-Lahargue, F.; Bikfalvi, A. Molecular mechanisms of tumor vascularization. Crit. Rev. Oncol. Hematol. 2005, 54, 53-61.
35. Maniotis, A.; Folberg, R.; Hess, A.; Seftor, E. A.; Gardner, L. M. G.; Pe'er, J.; Trent, J. M.; Meltzer, P. S.; Hendrix, M. J. C. Vascular channel formation by human melanoma cells in vivo and in vitro, vasculogenic mimicry. Am. J. Pathol. 1999, 155, 739-752.
36. Holash, J.; Maisonpierre, P. C.; Compton, D.; Boland, P.; Alexander, C. R.; Zagzag, D.; Yancopoulos, G. D.; Wiegang, S. J. Vessel cooption; regression; and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994-1998.
37. Wesseling, P.; Ruiter, D. J.; Burger, P. C. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol. 1997, 32, 253-265.
38. Leenders, W.; Kusters, B.; de Waal, R. Vessel co-option, how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9, 83-87.
39. Kusters, B.; Leenders, W. P.; Wesseling, P.; Smits, D.; Verrijp, K.; Ruiter, D. J.; Peters, J. P.; van der Kogel, A. J.; de Waal, R. M. Vascular endothelial growth factor-A165 induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002, 62, 341-345.
40. Kienast, Y.; von Baumgarten, L.; Fuhrmann, M.; Klinkert, W. E.; Goldbrunner, R.; Herms, J.; Winkler, F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16, 116-122.
41. Yadzani, S.; Miki, Y.; Tamaki, K.; Ono, K.; Iwabuchi, E.; Abe, K.; Suzuki, T.; Sato, Y.; Kondo, T.; Sasano H. Proliferation and maturation of intratumoral blood vessels in non-small cell lung cancer. Hum. Pathol. 2013, 44, 1586-1596.
42. Rivera, L. B.; Brekken, R. A. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J. Cell Biol. 2011, 193, 1305-1319.
43. Barresi, V.; Alafaci, C.; Salpietro, F.; Tuccari, G. Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade; proliferation or microvessel density? Oncol. Rep. 2008, 20, 485-492.
44. Barresi, V.; Vitarelli, E.; Tuccari, G.; Barresi, G. Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer. Arch. Pathol. Lab. Med. 2008, 132, 1807-1812.
45. Barresi, V.; Cerasoli, S.; Tuccari, G. Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 2008, 28, 472-478.
46. Barresi, V.; Vitarelli, E.; Cerasoli, S. Semaphorin3A immunohistochemical expression in human meningiomas, correlation with the microvessel density. Virchows Arch. 2009, 454, 563-571.
47. Barresi, V.; Tuccari, G.; Barresi, G. Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumor microvessel density. Pathology 2009, 41, 533-538.
48. Barresi, V.; di Gregorio, C.; Regiani-Bonetti, L.; Ponz-De Leon, M.; Barresi, G.; Vitarelli, E. Stage I colorectal carcinoma, VEGF immunohistochemical expression; microvessel density; and their correlation with clinical outcome. Virchows Arch. 2010, 457, 11-19.
49. Barresi, V.; Tuccari, G. Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology 2010, 30, 537-546.
50. Barresi, V. Angiogenesis in meningiomas. Brain Tumor. Pathol. 2011, 28, 99-106.
51. Barresi, V.; Branca, G.; Granata, F.; Alafaci, C.; Caffo, M.; Tuccari, G. Embolized meningiomas, risk of overgrading and neo-angiogenesis. J. Neurooncol. 2013, 113, 207-219.
52. Rosen, L. S.; Hurwitz, H. I.; Wong, M. K.; Goldman, J.; Mendelson, D. S.; Figg, W. D.; Spencer, S.; Adams, B. J.; Alvarez, D.; Seon, B. K.; et al. A phase I first-in-human study of TRC105 Anti-Endoglin Antibody in patients with advanced cancer. Clin. Cancer Res. 2012, 18, 4820-4829.
53. Paauwe, M.; ten Dijke, P.; Hawinkels, L. J. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin. Ther. Targets 2013, 17, 421-435.